Intralesional immunotherapy for wart treatment still has an uncertain mechanism of action but is repeatedly mentioned to be associated with an induced cell mediated immune response leading to upregulation of Th1 cytokine profile e.g. IFN-, TNF-, ILs 2& 12 mediating a cytotoxic response against virally infected cells not only in the injected warts but in non-injected distant warts as well [15]. The gene discussed is TNF; the disease is common wart.